|
1
|
Benjamins MR, Hunt BR, Raleigh SM,
Hirschtick JL and Hughes MM: Racial disparities in prostate cancer
mortality in the 50 Largest US Cities. Cancer Epidemiol.
44:125–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
James N, Pirrie S, Pope A, Barton D,
Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker
C, et al: TRAPEZE: A randomised controlled trial of the clinical
effectiveness and cost-effectiveness of chemotherapy with
zoledronic acid, strontium-89, or both, in men with bony metastatic
castration-refractory prostate cancer. Health Technol Assess.
20:1–288. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Slusarz A, Jackson GA, Day JK, Shenouda
NS, Bogener JL, Browning JD, Fritsche KL, MacDonald RS,
Besch-Williford CL and Lubahn DB: Aggressive prostate cancer is
prevented in ERαKO mice and stimulated in ERβKO TRAMP mice.
Endocrinology. 153:4160–4170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levakov AF, Kaćanski MM, Vucković N,
Zivojinov M, Amidzić J and Sabo JI: The expression and localization
of estrogen receptor beta in hyperplastic and neoplastic prostate
lesions. Vojnosanit Pregl. 72:906–913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Zhang P, Meng X, Chen X, Xiang Z,
Lin X, Liu Y, Gan W, Han X and Li D: Correlation between the
germline methylation status in ERβ promoter and the risk in
prostate cancer: A prospective study. Fam Cancer. 15:309–315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weihua Z, Warner M and Gustafsson JA:
Estrogen receptor beta in the prostate. Mol Cell Endocrinol.
193:1–5. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumar R, Verma V, Sharma V, Jain A, Singh
V, Sarswat A, Maikhuri JP, Sharma VL and Gupta G: A precisely
substituted benzopyran targets androgen refractory prostate cancer
cells through selective modulation of estrogen receptors. Toxicol
Appl Pharmacol. 283:187–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mahmoud AM, Al-Alem U, Ali MM and Bosland
MC: Genistein increases estrogen receptor beta expression in
prostate cancer via reducing its promoter methylation. J Steroid
Biochem Mol Biol. 152:62–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asgari M and Morakabati A: Estrogen
receptor beta expression in prostate adenocarcinoma. Diagn Pathol.
6:612011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Attia DM and Ederveen AG: Opposing roles
of ERα and ERβ in the genesis and progression of adenocarcinoma in
the rat ventral prostate. Prostate. 72:1013–1022. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Medeiros R, Vasconcelos A, Costa S, Pinto
D, Morais A, Oliveira J and Lopees C: Steroid hormone genotypes
ARStuI and ER325 are linked to the progression of human prostate
cancer. Cancer Genet Cytogenet. 141:91–96. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muthusamy S, Andersson S, Kim HJ, Butler
R, Waage L, Bergerheim U and Gustafsson JÅ: Estrogen receptor β and
17β-hydroxysteroiddeh ydrogenase type 6, a growth regulatory
pathway that is lost in prostate cancer. Proc Natl Acad Sci USA.
108:20090–20094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Signoretti S and Loda M: Estrogen receptor
beta in prostate cancer: brake pedal or accelerator? Am J Pathol.
159:13–16. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Megas G, Chrisofos M, Anastasiou I,
Tsitlidou A, Choreftaki T and Deliveliotis C: Estrogen receptor (α
and β) but not androgen receptor expression is correlated with
recurrence, progression and survival in post prostatectomy T3N0M0
locally advanced prostate cancer in an urban Greek population.
Asian J Androl. 17:98–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lombardi AP, Pisolato R, Vicente CM,
Lazari MF, Lucas TF and Porto CS: Estrogen receptor beta (ERβ)
mediates expression of β-catenin and proliferation in prostate
cancer cell line PC-3. Mol Cell Endocrinol. 430:12–24. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Royuela M, de Miguel MP, Bethencourt FR,
Sánchez-Chapado M, Fraile B, Arenas MI and Paniagua R: Estrogen
receptors alpha and beta in the normal, hyperplastic and
carcinomatous human prostate. J Endocrinol. 163:447–454. 2001.
View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bosland MC: Sex steroids and prostate
carcinogenesis: Integrated, multifactorial working hypothesis. Ann
N Y Acad Sci. 1089:168–176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thapa D and Ghosh R: Chronic inflammatory
mediators enhance prostate cancer development and progression.
Biochem Pharmacol. 94:53–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Alcaraz A, Hammerer P, Tubaro A, Schröder
FH and Castro R: Is there evidence of a relationship between benign
prostatic hyperplasia and prostate cancer? Findings of a literature
review. Eur Urol. 55:864–873. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Veldscholte J, Ris-Stalpers C, Kuiper GG,
Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J,
Brinkmann AO and Mulder E: A mutation in the ligand binding domain
of the androgen receptor of human LNCaP cells affects steroid
binding characteristics and response to anti-androgens. Biochem
Biophys Res Commun. 173:534–540. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suryavanshi M, Mehta A, Jaipuria J, Sharma
AK, Rawal S and Seth N: Weaker ERG expression in patients with
ERG-positive prostate cancer is associated with advanced disease
and weaker androgen receptor expression: An Indian outlook. Urol
Oncol. 33(331): e9–15. 2015.
|
|
24
|
Kleb B, Estécio MR, Zhang J, Tzelepi V,
Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, et al:
Differentially methylated genes and androgen receptor re-expression
in small cell prostatecarcinomas. Epigenetics. 11:184–193. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weihua Z, Ekman J, Almkvist A, Saji S,
Wang L, Warner M and Gustafsson JA: Involvement of androgen
receptor in 17beta-estradiol-induced cell proliferation in rat
uterus. Biol Reprod. 67:616–623. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
McPherson SJ, Ellem SJ, Simpson ER,
Patchev V, Fritzemeier KH and Risbridger GP: Essential role for
estrogen receptor beta in stromal-epithelial regulation of
prostatic hyperplasia. Endocrinology. 148:566–574. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lau KM, LaSpina M, Long J and Ho SM:
Expression of estrogen receptor (ER)-alpha and ER-beta in normal
and malignant prostatic epithelial cells: Regulation by methylation
and involvement in growth regulation. Cancer Res. 60:3175–3182.
2000.PubMed/NCBI
|
|
28
|
Cheng J, Lee EJ, Madison LD and Lazennec
G: Expression of estrogen receptor beta in prostate carcinoma cells
inhibits invasion and proliferation and triggers apoptosis. FEBS
Lett. 566:169–172. 2004. View Article : Google Scholar : PubMed/NCBI
|
